Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 170

1.

The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.

Volz T, Allweiss L, Ben MBarek M, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M.

J Hepatol. 2013 May;58(5):861-7. doi: 10.1016/j.jhep.2012.12.008. Epub 2012 Dec 13.

PMID:
23246506
[PubMed - indexed for MEDLINE]
2.

Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.

Lütgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok JM, Lohse AW, Petersen J, Urban S, Dandri M.

Hepatology. 2012 Mar;55(3):685-94. doi: 10.1002/hep.24758. Epub 2012 Jan 30.

PMID:
22031488
[PubMed - indexed for MEDLINE]
3.

Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection.

Giersch K, Helbig M, Volz T, Allweiss L, Mancke LV, Lohse AW, Polywka S, Pollok JM, Petersen J, Taylor J, Dandri M, Lütgehetmann M.

J Hepatol. 2014 Mar;60(3):538-44. doi: 10.1016/j.jhep.2013.11.010. Epub 2013 Nov 23.

PMID:
24280293
[PubMed - indexed for MEDLINE]
4.

Strategies to inhibit entry of HBV and HDV into hepatocytes.

Urban S, Bartenschlager R, Kubitz R, Zoulim F.

Gastroenterology. 2014 Jul;147(1):48-64. doi: 10.1053/j.gastro.2014.04.030. Epub 2014 Apr 25. Review.

PMID:
24768844
[PubMed - indexed for MEDLINE]
5.

In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice.

Lutgehetmann M, Volz T, Köpke A, Broja T, Tigges E, Lohse AW, Fuchs E, Murray JM, Petersen J, Dandri M.

Hepatology. 2010 Jul;52(1):16-24. doi: 10.1002/hep.23611.

PMID:
20578126
[PubMed - indexed for MEDLINE]
6.

Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes.

Sugiyama M, Tanaka Y, Kurbanov F, Maruyama I, Shimada T, Takahashi S, Shirai T, Hino K, Sakaida I, Mizokami M.

Gastroenterology. 2009 Feb;136(2):652-62.e3. doi: 10.1053/j.gastro.2008.10.048. Epub 2008 Oct 29.

PMID:
19041311
[PubMed - indexed for MEDLINE]
7.

Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.

Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R, Sültmann H, Urban S.

Gastroenterology. 2014 Apr;146(4):1070-83. doi: 10.1053/j.gastro.2013.12.024. Epub 2013 Dec 19.

PMID:
24361467
[PubMed - indexed for MEDLINE]
8.

Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.

Lutgehetmann M, Volzt T, Quaas A, Zankel M, Fischer C, Dandri M, Petersen J.

Antivir Ther. 2008;13(1):57-66.

PMID:
18389899
[PubMed - indexed for MEDLINE]
9.

Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes.

Lucifora J, Esser K, Protzer U.

Antiviral Res. 2013 Feb;97(2):195-7. doi: 10.1016/j.antiviral.2012.12.008. Epub 2012 Dec 21.

PMID:
23266293
[PubMed - indexed for MEDLINE]
10.

Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia.

Dandri M, Murray JM, Lutgehetmann M, Volz T, Lohse AW, Petersen J.

Hepatology. 2008 Oct;48(4):1079-86. doi: 10.1002/hep.22469.

PMID:
18697217
[PubMed - indexed for MEDLINE]
11.

Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection.

Protzer U, Seyfried S, Quasdorff M, Sass G, Svorcova M, Webb D, Bohne F, Hösel M, Schirmacher P, Tiegs G.

Gastroenterology. 2007 Oct;133(4):1156-65. Epub 2007 Jul 25.

PMID:
17919491
[PubMed - indexed for MEDLINE]
12.

A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.

Kosaka K, Hiraga N, Imamura M, Yoshimi S, Murakami E, Nakahara T, Honda Y, Ono A, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Aikata H, Ochi H, Ishida Y, Tateno C, Yoshizato K, Sasaki T, Chayama K.

Biochem Biophys Res Commun. 2013 Nov 8;441(1):230-5. doi: 10.1016/j.bbrc.2013.10.040. Epub 2013 Oct 16.

PMID:
24140055
[PubMed - indexed for MEDLINE]
13.

Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.

Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, Beld M, Reesink H.

J Gastroenterol Hepatol. 2011 Oct;26(10):1527-35. doi: 10.1111/j.1440-1746.2011.06766.x.

PMID:
21557773
[PubMed - indexed for MEDLINE]
14.

Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice.

Brezillon N, Brunelle MN, Massinet H, Giang E, Lamant C, DaSilva L, Berissi S, Belghiti J, Hannoun L, Puerstinger G, Wimmer E, Neyts J, Hantz O, Soussan P, Morosan S, Kremsdorf D.

PLoS One. 2011;6(12):e25096. doi: 10.1371/journal.pone.0025096. Epub 2011 Dec 5.

PMID:
22162746
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.

Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T, Karayiannis P.

J Hepatol. 2011 Jul;55(1):61-8. doi: 10.1016/j.jhep.2010.10.027. Epub 2010 Dec 5.

PMID:
21145875
[PubMed - indexed for MEDLINE]
16.

Chimeric mouse model for the infection of hepatitis B and C viruses.

Tesfaye A, Stift J, Maric D, Cui Q, Dienes HP, Feinstone SM.

PLoS One. 2013 Oct 14;8(10):e77298. doi: 10.1371/journal.pone.0077298. eCollection 2013.

PMID:
24155939
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz T, von Weizsäcker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S.

Nat Biotechnol. 2008 Mar;26(3):335-41. doi: 10.1038/nbt1389. Epub 2008 Feb 24.

PMID:
18297057
[PubMed - indexed for MEDLINE]
18.

The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents.

Ilan E, Burakova T, Dagan S, Nussbaum O, Lubin I, Eren R, Ben-Moshe O, Arazi J, Berr S, Neville L, Yuen L, Mansour TS, Gillard J, Eid A, Jurim O, Shouval D, Reisner Y, Galun E.

Hepatology. 1999 Feb;29(2):553-62.

PMID:
9918935
[PubMed - indexed for MEDLINE]
19.

EsiRNAs inhibit Hepatitis B virus replication in mice model more efficiently than synthesized siRNAs.

Xuan B, Qian Z, Hong J, Huang W.

Virus Res. 2006 Jun;118(1-2):150-5. Epub 2006 Jan 19.

PMID:
16423421
[PubMed - indexed for MEDLINE]
20.

Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model.

Wu J, Huang S, Zhao X, Chen M, Lin Y, Xia Y, Sun C, Yang X, Wang J, Guo Y, Song J, Zhang E, Wang B, Zheng X, Schlaak JF, Lu M, Yang D.

J Virol. 2014 Sep;88(18):10421-31. doi: 10.1128/JVI.00996-14. Epub 2014 Jun 11.

PMID:
24920792
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk